Underestimation of Vertebral Fractures After Denosumab Discontinuation.
Détails
![Ressource 1](https://serval.unil.ch/static/img/forbidden.png)
Accès restreint UNIL
Etat: Public
Version: de l'auteur⸱e
Licence: Non spécifiée
ID Serval
serval:BIB_4B76119EAB6D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Institution
Titre
Underestimation of Vertebral Fractures After Denosumab Discontinuation.
Périodique
Journal of bone and mineral research
ISSN
1523-4681 (Electronic)
ISSN-L
0884-0431
Statut éditorial
Publié
Date de publication
03/2018
Peer-reviewed
Oui
Volume
33
Numéro
3
Pages
547
Langue
anglais
Notes
Publication types: Letter
Publication Status: ppublish
Publication Status: ppublish
Résumé
We have read with interest the article on vertebral fractures after stopping Denosumab by Cummings SR et al. (1). Denosumab discontinuation is followed by a rebound effect with an increase of CTX above baseline values for two years and a decrease of BMD to baseline value after one year (2). Spontaneous clinical vertebral fractures, most often multiple, occur in the 8 to 16 months (median 11.2 months) following the last Denosumab injection (3). The risk of clinical vertebral fractures in the 12 months following the last Denosumab injection was evaluated at 7.3% (4). This risk is certainly higher with a follow-up of 16 months and the inclusion of non clinical fractures. Cummings SR et al. calculate an exposure-adjusted participant incidence of vertebral fractures (radiological and clinical) of 7.1 per 100 participant-years, from which only 39.3% where clinical fractures. We think that the difference between the previously published data and the actual study is due to the fact that the duration of the follow-up was not sufficient to capture all the vertebral fractures. Moreover, we found that this study has methodological caveats.
Mots-clé
Antiresorptives, CLINICAL TRIALS, DISEASES AND DISORDERS OF/RELATED TO BONE, DXA ANALYSIS/QUANTITATION OF BONE, Fracture risk assessment, Osteoporosis, PRACTICE/POLICY-RELATED ISSUES, THERAPEUTICS
Pubmed
Web of science
Création de la notice
08/02/2018 19:48
Dernière modification de la notice
23/01/2020 7:19